Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetrorelix versus placebo in recombinant FSH-stimulated IUI cycles
NL-OMON22749Not yet recruiting
- Sponsor
- none Serono Benelux B.V. will provide all centres with the necessary drugs
- Start
- Nov 2005
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of cetrorelix, follitropin alfa and recombinant human chorionic gonadotrophin in female infertility and male infertility (2 arms), sponsored by none Serono Benelux B.V. will provide all centres with the necessary drugs. Primary endpoint: Live birth rate per couple. Planned start Nov 2005; status: not yet recruiting.
02
Drugs
cetrorelixfollitropin alfarecombinant human chorionic gonadotrophin
03
Conditions
female infertilitymale infertility
Beyond the preview
Go deeper on NL-OMON22749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22749.